Mark Sullivan
Fondateur chez Medicines Development for Global Health Ltd
Profil
Mark Sullivan is the founder of Medicines Development for Global Health Ltd, which was founded in 2005.
He held the titles of Managing Director & Director.
Currently, he is a Venture Partner at Adjuvant Capital LP and a Senior Advisor at Global Health Funds LLC.
In the past, he worked as an Associate Director & Clinical Research at Gilead Sciences, Inc. from 2001 to 2003, as a Director-Asia Pacific at i3 Global from 1999 to 2000, as the Head-Development at Opthea Ltd.
from 2009 to 2012, and as the Chief Operating Officer at the University of New South Wales Built Environment from 2003 to 2005.
He received his undergraduate degree from Deakin University in 1998.
Postes actifs de Mark Sullivan
| Sociétés | Poste | Début |
|---|---|---|
Medicines Development for Global Health Ltd
 Medicines Development for Global Health Ltd Pharmaceuticals: MajorHealth Technology Medicines Development Ltd. engages in the development of medicines and vaccines. Its development programs include Moxidectin Program, Global Health Programs, and Consulting ervices. The company was founded by Mark Sullivan in 2005 and is headquartered in Melbourne, Australia. | Fondateur | 01/10/2005 |
Adjuvant Capital LP
 Adjuvant Capital LP Investment ManagersFinance Adjuvant Capital LP (Adjuvant Capital) is a private equity and venture capital firm founded in 2018 by Glenn Rockman, Kabeer Aziz and Charlie Petty. The firm is headquartered in New York. | Private Equity Investor | 01/07/2020 |
| Global Health Funds LLC | Consultant / Advisor | 01/12/2020 |
Anciens postes connus de Mark Sullivan
| Sociétés | Poste | Fin |
|---|---|---|
| OPTHEA LIMITED | Corporate Officer/Principal | 15/12/2012 |
| University of New South Wales Built Environment | Directeur des opérations | 30/09/2005 |
| GILEAD SCIENCES, INC. | Directeur/Membre du Conseil | 31/12/2003 |
i3 Global
 i3 Global Miscellaneous Commercial ServicesCommercial Services i3 Global operates as a pharmaceutical services company. It offers therapeutically specialized contract research solutions, clinical data services, staffing solutions, pharmacovigilance and epidemiology solutions. The company was founded in 1988 and is headquartered in Bernards, NJ. | Directeur/Membre du Conseil | 31/12/2000 |
Formation de Mark Sullivan
| Deakin University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| OPTHEA LIMITED | Health Technology |
| GILEAD SCIENCES, INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
Medicines Development for Global Health Ltd
Medicines Development for Global Health Ltd Pharmaceuticals: MajorHealth Technology Medicines Development Ltd. engages in the development of medicines and vaccines. Its development programs include Moxidectin Program, Global Health Programs, and Consulting ervices. The company was founded by Mark Sullivan in 2005 and is headquartered in Melbourne, Australia. | Health Technology |
Adjuvant Capital LP
Adjuvant Capital LP Investment ManagersFinance Adjuvant Capital LP (Adjuvant Capital) is a private equity and venture capital firm founded in 2018 by Glenn Rockman, Kabeer Aziz and Charlie Petty. The firm is headquartered in New York. | Finance |
| Global Health Funds LLC | |
i3 Global
i3 Global Miscellaneous Commercial ServicesCommercial Services i3 Global operates as a pharmaceutical services company. It offers therapeutically specialized contract research solutions, clinical data services, staffing solutions, pharmacovigilance and epidemiology solutions. The company was founded in 1988 and is headquartered in Bernards, NJ. | Commercial Services |
